Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer

Prior treatment

• Patients taking antiplatelet or anticoagulant drugs within the last week;

Other illness

• Infectious diseases (e.g. AIDS, syphilis, active tuberculosis);
• Patients with active hepatitis B or C infection;
• Combination of other primary malignant tumors;
• Patients with gastric cancer combined with active bleeding;
• patients with combined active infection or autoimmune disease;

Other

• Pregnant or breastfeeding women, or women with pregnancy plans within six months;
• Patients who have participated in a clinical trial within one month;
• Large amount of ascites (ascites ≥3000ml);
• Cardia obstruction or pyloric obstruction;
• Those who the doctor thinks there are other reasons not to be included in the treatment.

• Patients diagnosed with advanced gastric cancer (stage IV in AJCC 8th edition staging, including locally progressive gastric cancer with unresectable factors (IVa) and gastric cancer with distant metastases (IVb); Bowman's staging type I, II, and III), who are unable to be surgically resected or do not tolerate surgical resection, and who have undergone progression after 1-2 lines of conventional chemotherapy;
• Age greater than 18 years and less than 80 years;
• WHO pathology type: adenocarcinoma, neuroendocrine tumor;
• Expected survival greater than 3 months and controllable distant metastases as judged by the physician;
• Important organ functions must be met: ① Liver function: ALT and AST ≤ 2.5 times the positive range, total bilirubin ≤ 2.0mg/dL; ② Renal function: creatinine clearance ≥ 40mL/min calculated using the EPI formula;
• Blood routine: Hgb≥70g/L,ANC≥1.5×109/L,PLT≥80×109/L;
• Coagulation function: PT and APPT \<2 times the normal value;
• Pregnancy test must be negative in women of childbearing age;
• ECOG score ≤2;
• Signed informed consent.